Development
DexCom, Inc.
DXCM
$82.26
$1.642.03%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 26.90% | 26.69% | 25.15% | 17.92% | 16.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 26.90% | 26.69% | 25.15% | 17.92% | 16.76% |
| Cost of Revenue | 37.97% | 27.71% | 31.70% | 20.89% | 21.41% |
| Gross Profit | 21.30% | 26.12% | 21.56% | 16.20% | 14.54% |
| SG&A Expenses | 1.15% | 21.36% | 19.45% | 34.58% | 30.64% |
| Depreciation & Amortization | 8.77% | -5.56% | -10.53% | -10.00% | -507.14% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.53% | 23.69% | 20.03% | 18.18% | -1.12% |
| Operating Income | 72.97% | 39.32% | 66.36% | 14.29% | 20,800.00% |
| Income Before Tax | 84.83% | 64.43% | 111.55% | 78.67% | 1,981.25% |
| Income Tax Expenses | -124.40% | 166.00% | 77.87% | 125.98% | 253.85% |
| Earnings from Continuing Operations | 179.19% | 19.27% | 127.70% | -50.05% | 1,832.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 179.19% | 19.27% | 127.70% | -50.05% | 1,832.08% |
| EBIT | 72.97% | 39.32% | 66.36% | 14.29% | 20,800.00% |
| EBITDA | 66.60% | 35.89% | 42.45% | 13.70% | 1,000.00% |
| EPS Basic | 180.85% | 20.26% | 131.07% | -49.76% | 1,834.31% |
| Normalized Basic EPS | 84.71% | 65.78% | 114.76% | 79.66% | 1,949.52% |
| EPS Diluted | 180.98% | 18.67% | 122.63% | -48.61% | 1,719.71% |
| Normalized Diluted EPS | 88.06% | 64.03% | 106.54% | 83.08% | 1,759.05% |
| Average Basic Shares Outstanding | -0.57% | -0.82% | -1.48% | -0.57% | -0.44% |
| Average Diluted Shares Outstanding | -2.35% | 0.23% | 2.40% | -2.38% | 9.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |